3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Immunoglobulin Light-chain Amyloidosis
4
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Renal Insufficiency
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Thalassemia
1
Plasmablastic Lymphoma
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Leukemia, Biphenotypic, Acute
1
Burkitt Lymphoma
1
Anemia, Sickle Cell
1
Amyloidosis
1
Acute-Phase Reaction
1
Interventions
darolutamide
3
Pluvicto
3
Docetaxel
3
testosterone 17 beta-cypionate
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
ebastine
1
cabozantinib
1
cabazitaxel
1
Standard of Care
1
Prednisone
1
Prednisolone
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled